Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan

• मुख्य लेखकों: Chia-Chen Hsu (लेखक), Yu-Bin Pan (लेखक), Chyong-Huey Lai (लेखक), Ting-Chang Chang (लेखक), Lan-Yan Yang (लेखक), Hung-Hsueh Chou (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Elsevier, 2021-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Objective: The first Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor, olaparib, was approved by Taiwan Food and Drug Administration in June 2018, which was available under a compassionate use program since 2015. This study aims to report the early experience of the effectiveness and a...